A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer

References

• Colozza M, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Bringing molecular prognosis and prediction to the clinic. Clin Breast Cancer 2005; 6: 61–76
   PubMedGoogle Scholar
• Erdem O, Dursun A, Coskun U, Gunel N. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. Tumori 2005; 91: 46–52
   PubMedGoogle Scholar
• Look M, van PW, Duffy M, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost 2003; 90: 538–48
   PubMed Web of Science ®Google Scholar
• Offersen BV, Sørensen FB, Yilmaz M, Knoop A, Overgaard J. Chalkley estimates of angiogenesis in early breast cancer–relevance to prognosis. Acta Oncol 2002; 41: 695–703
   PubMed Web of Science ®Google Scholar
• Offersen BV, Sørensen FB, Knoop A, Overgaard J. The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 2003; 43: 573–82
   PubMed Web of Science ®Google Scholar
• Offersen BV, Riisbro R, Knoop A, Brunner N, Overgaard J. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer. Acta Oncol 2007; 46: 782–91
   PubMed Web of Science ®Google Scholar
• Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 1998; 58: 2166–9
   PubMed Web of Science ®Google Scholar
• Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 2000; 39: 327–33
   PubMed Web of Science ®Google Scholar
• Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 2000; 6: 3923–31
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12
   PubMed Web of Science ®Google Scholar
• Moasser, MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007.
   Google Scholar
• Petitjean A, Achatz MI, Børresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157–65
   PubMed Web of Science ®Google Scholar
• Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006; 12: 1157–67
   PubMed Web of Science ®Google Scholar
• Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004; 43: 35–42
   PubMed Web of Science ®Google Scholar
• Schlemmer BO, Sørensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexø E. Quantitative PCR–new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization. Scand J Clin Lab Invest 2004; 64: 511–22
   PubMed Web of Science ®Google Scholar
• Hansen LL, Andersen J, Overgaard J, Kruse TA. Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement. APMIS 1998; 106: 371–7
   PubMed Web of Science ®Google Scholar
• Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513–21
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007; 369: 29–36
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719–26
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354: 2103–11
   PubMed Web of Science ®Google Scholar
• Alsner, J , Jensen, V , Overgaard, J. A comparison among p53 expression and TP53 mutations as prognostic variables in tumours from 401 patients diagnosed with early breast cancer. Acta Oncol 2008;47:600–7.
   PubMed Web of Science ®Google Scholar